E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Participants with Pulmonary Arterial Hypertension |
Participantes con hipertensión arterial pulmonar |
|
E.1.1.1 | Medical condition in easily understood language |
Participants with high blood pressure in the arteries of the lungs |
Participantes con tension sanguínea alta en las arterias de los pulmones |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201, INS1009-202 and other lead-in studies of TPIP in participants with PAH. |
Evaluar la seguridad y tolerabilidad del uso a largo plazo de TPPI en participantes con HAP de los estudios INS1009-201, INS1009-202 y otros estudios de preinclusión de TPPI en participantes con HAP. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the effect of the long-term use of TPIP on exercise capacity in participants with PAH. - To evaluate the effect of the long-term use of TPIP on blood biomarkers of disease severity in participants with PAH. - To evaluate the effect of the long-term use of TPIP on the mortality risk in participants with PAH. - To evaluate the effect of the long-term use of TPIP on the clinical status of participants with PAH. - To evaluate the effect of the long-term use of TPIP on the clinical worsening rate in participants with PAH. - To further evaluate the PK profile of the long-term use of TPIP in participants with PAH. |
- Evaluar el efecto del uso a largo plazo de TPPI sobre la capacidad de realizar ejercicio en participantes con HAP. - Evaluar los efectos del uso a largo plazo de TPPI sobre los biomarcadores sanguíneos de la gravedad de la enfermedad en participantes con HAP. - Evaluar el efecto del uso a largo plazo de TPPI sobre el riesgo de mortalidad en participantes con HAP. - Evaluar el efecto del uso a largo plazo de TPPI sobre el estado clínico de los participantes con HAP. - Evaluar el efecto del uso a largo plazo de TPPI sobre la tasa de empeoramiento clínico en participantes con HAP. - Evaluar más a fondo el perfil FC del uso a largo plazo de TPPI en participantes con HAP. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Participants who completed the end of treatment visit in Study INS1009-201, Study INS1009-202, or any other lead-in PAH TPIP study. Participants for whom the OLE study was not available at the time of their completion of the lead-in study are eligible for enrolment within one year of their lead-in end of treatment visit. 2. Complete baseline screening assessments to confirm eligibility to participate if more than 30 days have elapsed since the end of the study visit in Study INS1009-201, Study INS1009-202, or any other lead-in PAH TPIP in study. 3. Capable of giving signed informed consent. |
1. Participantes que completaron la visita de fin de tratamiento en el estudio INS1009-201, INS1009-202 o cualquier otro estudio de preinclusión de TPPI para la HAP. Los participantes para los que el estudio AAE no estaba disponible en el momento de completar el estudio de preinclusión son elegibles para inscribirse al cabo de un año de su visita de fin de tratamiento del estudio de preinclusión. 2. Evaluaciones de selección iniciales completas que confirmen la elegibilidad para participar si han transcurrido más de 30 días desde la visita de fin de estudio en el estudio INS1009-201, estudio INS1009-202 o cualquier otro estudio de preinclusión con TPPI para la HAP. 3. Capacidad de dar el consentimiento informado firmado. |
|
E.4 | Principal exclusion criteria |
1. Participants who experienced any hypersensitivity or adverse drug reaction or were withdrawn early/discontinued in a previous PAH TPIP study, which, in the opinion of the Investigator, could indicate that continued treatment with TPIP may present an unreasonable risk for the participant. 2. Initiation of parenteral administration of prostacyclin analogues (eg, TRE, epoprostenol) since the completion of studies INS1009-201, INS1009-202 or other TPIP studies. Initiation of inhaled prostacyclin analogues (eg, TRE [Tyvaso®] or iloprost) and oral prostacyclin analogues (eg, TRE [Orenitram®]) or receptor agonists (eg, selexipag) are permitted if stopped 24 hours prior to the start of study drug administration. 3. Pregnant or breastfeeding. 4. Any medical or psychological condition, including relevant laboratory abnormalities, at screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease that may present an unreasonable risk to the study participant as a result of participation in the study. |
1. Participantes que experimentaron cualquier hipersensibilidad o reacción adversa al medicamento o fueron retirados/discontinuados anticipadamente en un estudio previo de TPPI para la HAP, lo que, en opinión del investigador, podría indicar que continuar el tratamiento con TPPI puede presentar un riesgo irrazonable para el participante. 2. Inicio de la administración parenteral de análogos de prostaciclina (por ejemplo, TRE, epoprostenol) desde la finalización de los estudios INS1009-201, INS1009-202 u otros estudios de TPPI. Se permite el inicio de análogos de prostaciclina inhalados (por ejemplo, TRE [Tyvaso®] o iloprost) y análogos orales de prostaciclina (por ejemplo, TRE [Orenitram®]) o agonistas del receptor (por ejemplo, selexipag) si se suspenden 24 horas antes del inicio de la administración del fármaco del estudio. 3. Embarazo o lactancia. 4. Cualquier afección médica o psicológica, incluidas las anomalías de laboratorio relevantes en la selección que, en opinión del investigador, sugiera una enfermedad nueva o insuficientemente entendida que pueda presentar un riesgo irrazonable para el participante del estudio como resultado de la participación en el estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Frequency and severity of TEAEs |
Frecuencia y gravedad de los AAST |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the study. |
A lo largo del estudio. |
|
E.5.2 | Secondary end point(s) |
- Change in 6MWD (absolute and relative). - Change in the concentration of NT-proBNP in blood. - Change in the REVEAL Lite 2.0 score. - Annualized rate of clinical worsening events (as defined in the protocol) - Plasma concentration levels of TP and TRE. |
- Cambio en la DR6M (absoluto y relativo). - Cambio en la concentración de NT-proBNP en sangre. - Cambio en la puntuación REVEAL Lite 2.0. - Tasa anualizada de acontecimientos de empeoramiento clínico (como se define en el protocolo). - Niveles de concentración plasmática de TP y TRE. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- From pre-OLE baseline* to Month 6, Month 12, Month 18, and Month 24 - From pre-OLE baseline* to Month 6, Month 12, Month 18, and Month 24 - From pre-OLE baseline* to Month 6, Month 12, Month 18, and Month 24 - Throughout the study - Throughout the study |
- Desde el inicio antes del OLE* hasta el mes 6, mes 12, mes 18 y mes 24 - Desde el inicio antes del OLE* hasta el mes 6, mes 12, mes 18 y mes 24 - Desde el inicio antes del OLE* hasta el mes 6, mes 12, mes 18 y mes 24 - A lo largo del estudio - A lo largo del estudio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tolerabilidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Período ajuste dosis enmascarado 3 semanas para participantes incluidos del estudio de preinclusión |
3-week blinded titration period for participants enrolling immediately from a lead in study. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Japan |
Malaysia |
Mexico |
Peru |
Philippines |
United States |
Austria |
Spain |
Switzerland |
Germany |
Italy |
Belgium |
Denmark |
United Kingdom |
Serbia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the date of the last Follow-Up phone call or visit for the last participant in the study. |
El final del estudio se define como la fecha de la última visita o llamada telefónica de seguimiento al último participante en el estudio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |